Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated Daratumumab Infusion in Multiple Myeloma
NCT02944565Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Feb 2017
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Feb 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02944565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944565.